Baishan Jiang, Ph.D

Affiliations: 
2015- Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA, United States 
Google:
"Baishan Jiang"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Gui F, Jiang B, Jiang J, et al. (2025) Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer. Science Advances. 11: eadu0847
Jiang B, Chen L, Huang L, et al. (2025) Selective and Potent Molecular Glue Degraders for NIMA-related Kinase 7. Angewandte Chemie (International Ed. in English). e202500169
Huang L, Chen L, Chen L, et al. (2024) Development of Oral, Potent, and Selective CK1α Degraders for AML Therapy. Jacs Au. 4: 4423-4434
Gui F, Jiang B, Jiang J, et al. (2024) Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer. Biorxiv : the Preprint Server For Biology
Ye M, Fang Y, Chen L, et al. (2024) Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability. Nature Communications. 15: 2377
Kumarasamy V, Gao Z, Zhao B, et al. (2023) PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies. British Journal of Cancer
Koide E, Mohardt ML, Doctor ZM, et al. (2023) Development and characterization of selective FAK inhibitors and PROTACs with in vivo activity. Chembiochem : a European Journal of Chemical Biology. e202300141
Gao Y, Jiang B, Kim H, et al. (2023) Catalytic Degraders Effectively Address Kinase Site Mutations in EML4-ALK Oncogenic Fusions. Journal of Medicinal Chemistry
Jiang B, Weinstock DM, Donovan KA, et al. (2023) ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas. Cell Chemical Biology. 30: 383-393.e6
Gao X, Wu Y, Chick JM, et al. (2023) Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance. Cell Reports. 42: 112314
See more...